P2 receptors, platelet function and pharmacological implications

被引:215
作者
Gachet, Christian [1 ,2 ]
机构
[1] EFS Alsace, INSERM, U311, F-67065 Strasbourg, France
[2] Univ Strasbourg, Strasbourg, France
关键词
haemostasis; thrombosis; ADP; P2Y(1); P2Y(12); P2X(1); antiplatelet drugs; thienopyridine; clopidogrel; prasugrel; AZD6140; cangrelor;
D O I
10.1160/TH07-11-0673
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ADP and ATP play a crucial role in platelet activation and their receptors are potential targets for antithrombotic drugs. The ATP-gated cation channel P2X(1) and the two G protein-coupled ADP receptors, P2Y(1) and P2Y(12), selectively contribute to platelet aggregation and formation of a thrombus. Owing to its central role in the growth and stabilization of a thrombus,the P2Y(12) receptor is an established target of antithrombotic drugs like the thienopyridines clopidogrel or prasugrel, or competitive antagonists such as cangrelor or AZD6140. The optimal inhibition of this receptor to reach clinical efficacy while preserving patients from unacceptable bleeding is a matter of debate. On the other hand, studies in P2Y(1) and P2X(1) knockout mice and using selective P2Y(1) and P2X(1) antagonists have shown that these receptors are also attractive targets for new antithrombotic compounds. Finally, the regulation by the P2 receptors of the platelet involvement in inflammatory processes is also briefly discussed.
引用
收藏
页码:466 / 472
页数:7
相关论文
共 104 条
  • [1] Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases
    Aleil, B
    Ravanat, C
    Cazenave, JP
    Rochoux, G
    Heitz, A
    Gachet, C
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (01) : 85 - 92
  • [2] ADP receptor antagonism - What's in the pipeline?
    Angiolillo, Dominick J.
    [J]. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2007, 7 (06) : 423 - 432
  • [3] Platelet function testing and cardiovascular outcomes: Steps forward in identifying the best predictive measure
    Angiolillo, Dominick J.
    Alfonso, Fernando
    [J]. THROMBOSIS AND HAEMOSTASIS, 2007, 98 (04) : 707 - 709
  • [4] Baurand A, 2000, THROMB HAEMOSTASIS, V84, P484
  • [5] Differential regulation and relocalization of the platelet P2Y receptors after activation:: A way to avoid loss of hemostatic properties?
    Baurand, A
    Eckly, A
    Hechler, B
    Kauffenstein, G
    Galzi, JL
    Cazenave, JP
    Léon, C
    Gachet, C
    [J]. MOLECULAR PHARMACOLOGY, 2005, 67 (03) : 721 - 733
  • [6] Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist
    Baurand, A
    Raboisson, P
    Freund, M
    Léon, C
    Cazenave, JP
    Bourguignon, JJ
    Gachet, C
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 412 (03) : 213 - 221
  • [7] Scientific and therapeutic advances in antiplatelet therapy
    Bhatt, DL
    Topol, EJ
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (01) : 15 - 28
  • [8] ADENOSINE-DIPHOSPHATE AS A MEDIATOR OF PLATELET-AGGREGATION INVIVO - AN EDITORIAL VIEW
    BORN, GVR
    [J]. CIRCULATION, 1985, 72 (04) : 741 - 746
  • [9] Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
    Brandt, J. T.
    Close, S. L.
    Iturria, S. J.
    Payne, C. D.
    Farid, N. A.
    Ernest, C. S., II
    Lachno, D. R.
    Salazar, D.
    Winters, K. J.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (12) : 2429 - 2436
  • [10] A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation
    Brandt, John T.
    Payne, Christopher D.
    Wiviott, Stephen D.
    Weerakkody, Govinda
    Farid, Nagy A.
    Small, David S.
    Jaknbowski, Joseph A.
    Naganuma, Hideo
    Winters, Kenneth J.
    [J]. AMERICAN HEART JOURNAL, 2007, 153 (01) : 66.e9 - 66.e16